The role of combination medical therapy in the treatment of acromegaly

[1]  D. Figarella-Branger,et al.  In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells , 2016, Endocrine-related cancer.

[2]  M. Fleseriu,et al.  Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study , 2016, BMC Endocrine Disorders.

[3]  L. Moilanen,et al.  Mortality in acromegaly: a 20-year follow-up study. , 2015, Endocrine-related cancer.

[4]  M. Galderisi,et al.  Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly , 2015, Endocrine.

[5]  A. J. van der Lely,et al.  Combined treatment of somatostatin analogues with pegvisomant in acromegaly , 2015, Endocrine.

[6]  J. Jørgensen,et al.  Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3. , 2015, European journal of endocrinology.

[7]  L. Kasuki,et al.  Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly , 2015, Pituitary.

[8]  A. Colao,et al.  The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly , 2015, Pituitary.

[9]  J. Wass,et al.  60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly. , 2015, The Journal of endocrinology.

[10]  A. Colao,et al.  Adverse events associated with somatostatin analogs in acromegaly , 2015, Expert opinion on drug safety.

[11]  A. J. van der Lely,et al.  Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[12]  A. Colao,et al.  Cabergoline use for pituitary tumors and valvular disorders. , 2015, Endocrinology and metabolism clinics of North America.

[13]  P. Chanson.  Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs , 2015, Neuroendocrinology.

[14]  G. Johannsson,et al.  Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. , 2015, The Journal of clinical endocrinology and metabolism.

[15]  L. Denaro,et al.  Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center , 2015, Journal of Neuro-Oncology.

[16]  M. Fleseriu,et al.  Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. , 2014, The lancet. Diabetes & endocrinology.

[17]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[18]  M. Buchfelder,et al.  Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. , 2014, The Journal of clinical endocrinology and metabolism.

[19]  M. Fleseriu,et al.  Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. , 2014, Journal of molecular endocrinology.

[20]  S. Melmed,et al.  Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis , 2014, The Journal of clinical endocrinology and metabolism.

[21]  M. Fleseriu,et al.  Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study , 2014, The Journal of clinical endocrinology and metabolism.

[22]  A. Tabarin,et al.  Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial , 2013, The Journal of clinical endocrinology and metabolism.

[23]  J. Wass,et al.  Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists , 2013, Clinical endocrinology.

[24]  M. Fleseriu.  The role of combination medical therapy in acromegaly: hope for the nonresponsive patient , 2013, Current opinion in endocrinology, diabetes, and obesity.

[25]  F. Bogazzi,et al.  Effects of medical therapies for acromegaly on glucose metabolism. , 2013, European journal of endocrinology.

[26]  M. Gadelha,et al.  The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[27]  V. Toscano,et al.  Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes , 2013, Journal of experimental & clinical cancer research : CR.

[28]  E. Oldfield,et al.  Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. , 2013, The Journal of clinical endocrinology and metabolism.

[29]  S. Yamada,et al.  Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. , 2013, Endocrine journal.

[30]  S. Gultekin,et al.  Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience , 2013, Pituitary.

[31]  P. Chanson,et al.  A consensus on the diagnosis and treatment of acromegaly complications , 2012, Pituitary.

[32]  D. Figarella-Branger,et al.  Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment , 2012, Clinical endocrinology.

[33]  P. Chanson,et al.  No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. , 2012, The Journal of clinical endocrinology and metabolism.

[34]  F. Casanueva,et al.  Pegvisomant and cabergoline combination therapy in acromegaly , 2012, Pituitary.

[35]  V. Torri,et al.  Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly , 2012, PloS one.

[36]  M. Gadelha,et al.  Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs , 2012, Journal of Endocrinological Investigation.

[37]  G. Arnaldi,et al.  Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. , 2012, The Journal of clinical endocrinology and metabolism.

[38]  W. Drake,et al.  Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. , 2012, The Journal of clinical endocrinology and metabolism.

[39]  M. Gadelha,et al.  Aortic root ectasia in patients with acromegaly: experience at a single center , 2011, Clinical endocrinology.

[40]  A. Colao,et al.  Aortic root ectasia in patients with acromegaly: an emerging complication * , 2011, Clinical endocrinology.

[41]  S. Ezzat,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[42]  A. Beckers,et al.  Familial pituitary tumor syndromes. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[43]  E. Laws,et al.  Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. , 2011, The Journal of clinical endocrinology and metabolism.

[44]  H. Orskov,et al.  Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. , 2011, The Journal of clinical endocrinology and metabolism.

[45]  E. Chang,et al.  Excess mortality for patients with residual disease following resection of pituitary adenomas , 2011, Pituitary.

[46]  A. Colao,et al.  Resistance to somatostatin analogs in acromegaly. , 2011, Endocrine reviews.

[47]  P. Caron,et al.  Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. , 2011, European journal of endocrinology.

[48]  W. Ludlam.  Place of Cabergoline in Acromegaly: A Meta-Analysis , 2011 .

[49]  M. Bidlingmaier,et al.  Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly , 2012, Pituitary.

[50]  L. Vilar,et al.  Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR , 2011, Pituitary.

[51]  A. J. van der Lely,et al.  Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients , 2011, Pituitary.

[52]  M. Fleseriu.  Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review , 2010, Pituitary.

[53]  J. Abucham,et al.  Short- and Long-Term Efficacy of Combined Cabergoline and Octreotide Treatment in Controlling IGF-I Levels in Acromegaly , 2010, Neuroendocrinology.

[54]  P. Chanson,et al.  A consensus on criteria for cure of acromegaly. , 2010, The Journal of clinical endocrinology and metabolism.

[55]  G. Valk,et al.  Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. , 2010, European journal of endocrinology.

[56]  Michael Buchfelder,et al.  Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. , 2010, The Journal of clinical endocrinology and metabolism.

[57]  S. Melmed.  Acromegaly pathogenesis and treatment. , 2009, The Journal of clinical investigation.

[58]  S. Ezzat,et al.  A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly , 2009, Clinical endocrinology.

[59]  O. Dekkers,et al.  Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. , 2009, The Journal of clinical endocrinology and metabolism.

[60]  M. Andersen,et al.  Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. , 2009, European journal of endocrinology.

[61]  S. Clark,et al.  Low O6‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours , 2009, Clinical endocrinology.

[62]  S. Cannavò,et al.  High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. , 2009, European journal of endocrinology.

[63]  D. Russell-Jones,et al.  Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[64]  M. Buchfelder,et al.  Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. , 2009, European journal of endocrinology.

[65]  R. Kineman,et al.  Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[66]  M. Bronstein,et al.  Optimizing Medical Therapy of Acromegaly: Beneficial Effects of Cabergoline in Patients Uncontrolled with Long-Acting Release Octreotide , 2009, Neuroendocrinology.

[67]  P. Chanson,et al.  Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. , 2009, The Journal of clinical endocrinology and metabolism.

[68]  A. J. van der Lely,et al.  Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. , 2009, European journal of endocrinology.

[69]  Jeffrey W. Clark,et al.  O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors , 2008 .

[70]  W. Drake,et al.  Successful use of weekly pegvisomant administration in patients with acromegaly. , 2008, European journal of endocrinology.

[71]  W. Ludlam.  Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas , 2009 .

[72]  G. Mazziotti,et al.  Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review , 2009, Pituitary.

[73]  A. Saveanu,et al.  Somatostatin–dopamine ligands in the treatment of pituitary adenomas , 2009, Reviews in Endocrine and Metabolic Disorders.

[74]  X. Badia,et al.  Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. , 2009, The Journal of clinical endocrinology and metabolism.

[75]  Jeroen J. Bax,et al.  Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. , 2008, The Journal of clinical endocrinology and metabolism.

[76]  R. Murray,et al.  A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. , 2008, The Journal of clinical endocrinology and metabolism.

[77]  G. Gamble,et al.  A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. , 2008, European journal of endocrinology.

[78]  Jeroen J. Bax,et al.  Increased aortic root diameters in patients with acromegaly. , 2008, European journal of endocrinology.

[79]  J. Vandenbroucke,et al.  Mortality in acromegaly: a metaanalysis. , 2008, The Journal of clinical endocrinology and metabolism.

[80]  A. Colao,et al.  Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. , 2007, European journal of endocrinology.

[81]  J. Wardlaw,et al.  A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly , 2007, Clinical endocrinology.

[82]  A. Pontecorvi,et al.  Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA , 2007, Pituitary.

[83]  H. Orskov,et al.  The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. , 2007, The Journal of clinical endocrinology and metabolism.

[84]  M. Culler,et al.  Novel chimeric somatostatin analogs: facts and perspectives. , 2007, European journal of endocrinology.

[85]  A. J. van der Lely,et al.  Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. , 2007, The Journal of clinical endocrinology and metabolism.

[86]  M. Buchfelder,et al.  Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. , 2007, European journal of endocrinology.

[87]  A. J. van der Lely,et al.  Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. , 2006, European journal of endocrinology.

[88]  Stefania Gelmini,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(11):6156–6161 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2005-0633 Expression of the Antiapoptotic Gene Seladin-1 and Octreotide-Induced Apoptosis , 2005 .

[89]  J. Frystyk,et al.  Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. , 2005, The Journal of clinical endocrinology and metabolism.

[90]  M. Vance,et al.  Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. , 2005, The Journal of clinical endocrinology and metabolism.

[91]  Doan Huu Hau,et al.  Re‐evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients , 2005, Clinical endocrinology.

[92]  D. Rabinowitz,et al.  Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[93]  J. Janssen,et al.  Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly , 2005, The Lancet.

[94]  D. Selvarajah,et al.  Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. , 2005, European journal of endocrinology.

[95]  J. Bevan.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[96]  J. Taylor,et al.  BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. , 2005, Journal of endocrinological investigation.

[97]  G. Lasio,et al.  Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status , 2004, Clinical endocrinology.

[98]  G. Gamble,et al.  Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[99]  A. Khandji,et al.  Cabergoline Therapy of Growth Hormone & Growth Hormone/Prolactin Secreting Pituitary Tumors , 2004, Pituitary.

[100]  P. Marzullo,et al.  Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients , 2004, Pituitary.

[101]  W. Drake,et al.  Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. , 2003, European journal of endocrinology.

[102]  D. Clemmons,et al.  Growth hormone receptor antagonist improves insulin resistance in acromegaly. , 2002, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[103]  J. A. Scarlett,et al.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist , 2001, The Lancet.

[104]  M. Papotti,et al.  Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. , 2001, The Journal of clinical endocrinology and metabolism.

[105]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[106]  J. A. Scarlett,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000, The New England journal of medicine.

[107]  P. Black,et al.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.

[108]  A. Barkan,et al.  Treatment of acromegaly with dopamine agonists. , 1992, Endocrinology and metabolism clinics of North America.

[109]  P. Gorden,et al.  Echocardiographic assessment of cardiac anatomy and function in acromegalic patients. , 1979, The American journal of medicine.

[110]  A. Liuzzi,et al.  Inhibitory effect of dopaminergic stimulation on GH release in acromegaly. , 1974, The Journal of clinical endocrinology and metabolism.